Cancer patients undergoing abdominal surgery develop significant amino acid imbalances in the immediate postoperative period. Combined parenteral and enteral nutrition partially corrects these metabolic disturbances, though two different formulations produced equivalent results.
Surgical trauma in cancer patients creates a predictable metabolic crisis. This secondary analysis of a randomized controlled trial examined 120 patients with gastrointestinal or gynecological cancers who underwent abdominal surgery and spent at least 5 days in the ICU receiving nutritional support. At baseline (within 24-48 hours after surgery), the researchers documented a constellation of amino acid abnormalities: depressed branched-chain amino acid to aromatic amino acid ratios (BCAA/AAA), unstable urea cycle metabolism markers, elevated oxidative stress (measured via malondialdehyde), and disrupted arginine/ornithine/citrulline ratios.
These aren't minor biochemical ripples. The imbalances correlated with disease severity on the SOFA score (a standard ICU acuity measure) and negative nitrogen balance, indicating net protein catabolism. The researchers chose to track composite indices because single amino acids often fail to capture the complexity of postoperative metabolism: the BCAA/AAA ratio reflects the balance between amino acids that muscle preferentially consumes versus those that accumulate in liver disease, while urea cycle stability indicates whether the body can properly dispose of ammonia generated from protein breakdown.
When patients received combined nutrition support, improvements occurred across both groups. The BCAA/AAA ratio improved, the integrated urea cycle index stabilized, and ornithine-citrulline ratios normalized. Critically, the rate and magnitude of these corrections were equivalent whether patients received Aminoven 10% or Aminoparcentin, two different parenteral amino acid formulations. Both groups received 10 mL/kg of their assigned formulation plus 10% dextrose alongside early enteral feeding. The correlations between amino acid index improvements and changes in SOFA scores, malondialdehyde levels, and nitrogen balance ranged from moderate to strong (rho = 0.4-0.6, p < 0.05), suggesting that correction of amino acid imbalance tracks with overall metabolic recovery. However, correlation with cystatin C (a kidney function marker) was weak, indicating these nutritional interventions don't directly improve organ function markers in parallel.
This research has limited direct application to non-ICU populations but clarifies several principles relevant to postoperative recovery:
Amino acid balance matters after major surgery. The imbalances observed here reflect the catabolic state that any major surgery triggers. This is why protein-at-every-meal and early mobilization become priorities post-surgery rather than waiting until later in recovery. The study doesn't tell us whether healthy people need supplemental BCAA formulations specifically, but it does show that amino acid composition of nutrition support tracks with overall recovery markers.
Different formulations may be functionally equivalent. The lack of differences between the two parenteral nutrition products suggests that achieving adequate total amino acid intake matters more than selecting a specific brand or formulation. This is a negative finding (showing equivalence), which is less exciting but practically useful: it indicates clinicians have flexibility without sacrificing outcomes.
Partial correction is the realistic expectation. The improvements were real but didn't normalize amino acid profiles completely. Even with optimized nutrition support, ICU patients in the immediate postsurgical period remain in an altered metabolic state. Recovery is gradual.
Monitoring matters in severe illness. This study enrolled ICU patients with measurable organ dysfunction. If you or a family member undergoes major surgery requiring ICU care, these amino acid and oxidative stress markers might be worth tracking as part of a comprehensive recovery assessment, though the study doesn't recommend specific targets for clinical practice.
| Aspect | Detail |
|---|---|
| Study type | Randomized controlled trial (secondary analysis) |
| Sample size | 120 patients |
| Patient population | Ages 18-80; cancer patients undergoing abdominal surgery requiring ≥5 days ICU support |
| Intervention | Parenteral nutrition: Aminoven 10% vs. Aminoparcentin (10 mL/kg) + 10% dextrose + early enteral feeding |
| Measurements | Amino acid profiles (BCAA, AAA, arginine, ornithine, citrulline); composite indices (BCAA/AAA ratio, UreaCycle score, arginine ratios); malondialdehyde (oxidative stress); cystatin C; SOFA score; nitrogen balance; albumin |
| Time points | Baseline (T0, ~24-48h post-op), T1, T2 (follow-up intervals not specified in abstract) |
| Primary finding | Both formulations improved amino acid indices comparably; improvements correlated with SOFA score and nitrogen balance |
| Statistical methods | Non-parametric (Mann-Whitney U, Wilcoxon); Spearman correlations |
| Bias concerns | Sponsored by Medical Leasing-Consulting LLC (manufacturer of both study drugs); however, sponsor reportedly did not participate in analysis or writing |
| Evidence tier | : RCT with adequate sample size, but secondary analysis and narrowly defined ICU population limit generalizability |
PubMed: 42160147
Journal: Khirurgiia (Russian surgical journal)
Study population note: This research applies specifically to cancer patients requiring intensive care after abdominal surgery. Findings do not extend to routine elective surgery or non-surgical populations.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.